211 related articles for article (PubMed ID: 7568626)
1. LSD and structural analogs: pharmacological evaluation at D1 dopamine receptors.
Watts VJ; Lawler CP; Fox DR; Neve KA; Nichols DE; Mailman RB
Psychopharmacology (Berl); 1995 Apr; 118(4):401-9. PubMed ID: 7568626
[TBL] [Abstract][Full Text] [Related]
2. Dopamine D1 receptors: efficacy of full (dihydrexidine) vs. partial (SKF38393) agonists in primates vs. rodents.
Watts VJ; Lawler CP; Gilmore JH; Southerland SB; Nichols DE; Mailman RB
Eur J Pharmacol; 1993 Sep; 242(2):165-72. PubMed ID: 7902811
[TBL] [Abstract][Full Text] [Related]
3. Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes.
Borroto-Escuela DO; Romero-Fernandez W; Narvaez M; Oflijan J; Agnati LF; Fuxe K
Biochem Biophys Res Commun; 2014 Jan; 443(1):278-84. PubMed ID: 24309097
[TBL] [Abstract][Full Text] [Related]
4. Unsurmountable antagonism of brain 5-hydroxytryptamine2 receptors by (+)-lysergic acid diethylamide and bromo-lysergic acid diethylamide.
Burris KD; Sanders-Bush E
Mol Pharmacol; 1992 Nov; 42(5):826-30. PubMed ID: 1359397
[TBL] [Abstract][Full Text] [Related]
5. Binding sites for [3H]SCH 23390 in retina: properties and possible relationship to dopamine D1-receptors mediating stimulation of adenylate cyclase.
Makman MH; Dvorkin B
Brain Res; 1986 Dec; 387(3):261-70. PubMed ID: 2950967
[TBL] [Abstract][Full Text] [Related]
6. Interactions between lysergic acid diethylamide and dopamine-sensitive adenylate cyclase systems in rat brain.
Hungen KV; Roberts S; Hill DF
Brain Res; 1975 Aug; 94(1):57-66. PubMed ID: 238721
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of the D1- and D2-like dopamine receptors from the brain of the leopard frog, Rana pipiens.
Chu J; Wilczynski W; Wilcox RE
Brain Behav Evol; 2001 Jun; 57(6):328-42. PubMed ID: 11713387
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA).
Halberstadt AL; Klein LM; Chatha M; Valenzuela LB; Stratford A; Wallach J; Nichols DE; Brandt SD
Psychopharmacology (Berl); 2019 Feb; 236(2):799-808. PubMed ID: 30298278
[TBL] [Abstract][Full Text] [Related]
9. The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT
De Gregorio D; Posa L; Ochoa-Sanchez R; McLaughlin R; Maione S; Comai S; Gobbi G
Pharmacol Res; 2016 Nov; 113(Pt A):81-91. PubMed ID: 27544651
[TBL] [Abstract][Full Text] [Related]
10. Molecular cloning and expression of the rhesus macaque D1 dopamine receptor gene.
Machida CA; Searles RP; Nipper V; Brown JA; Kozell LB; Neve KA
Mol Pharmacol; 1992 Apr; 41(4):652-9. PubMed ID: 1533268
[TBL] [Abstract][Full Text] [Related]
11. Interaction between LSD and dopamine D2/3 binding sites in pig brain.
Minuzzi L; Nomikos GG; Wade MR; Jensen SB; Olsen AK; Cumming P
Synapse; 2005 Jun; 56(4):198-204. PubMed ID: 15803496
[TBL] [Abstract][Full Text] [Related]
12. Autoradiographic identification of D1 dopamine receptors labelled with [3H]dopamine: distribution, regulation and relationship to coupling.
Hervé D; Trovero F; Blanc G; Glowinski J; Tassin JP
Neuroscience; 1992; 46(3):687-700. PubMed ID: 1532052
[TBL] [Abstract][Full Text] [Related]
13. Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives.
Huang X; Marona-Lewicka D; Pfaff RC; Nichols DE
Pharmacol Biochem Behav; 1994 Mar; 47(3):667-73. PubMed ID: 8208787
[TBL] [Abstract][Full Text] [Related]
14. Dopaminergic benzo[a]phenanthridines: resolution and pharmacological evaluation of the enantiomers of dihydrexidine, the full efficacy D1 dopamine receptor agonist.
Knoerzer TA; Nichols DE; Brewster WK; Watts VJ; Mottola D; Mailman RB
J Med Chem; 1994 Jul; 37(15):2453-60. PubMed ID: 7914538
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of behavioural responses to SK&F 83959 in relation to 'D1-like' dopamine receptors not linked to adenylyl cyclase.
Deveney AM; Waddington JL
Br J Pharmacol; 1995 Oct; 116(3):2120-6. PubMed ID: 8640354
[TBL] [Abstract][Full Text] [Related]
16. Improved models for pharmacological null experiments: calculation of drug efficacy at recombinant D1A dopamine receptors stably expressed in clonal cell lines.
Mak CK; Avalos M; Randall PK; Kwan SW; Abell CW; Neumeyer JL; Whisennand R; Wilcox RE
Neuropharmacology; 1996 May; 35(5):549-70. PubMed ID: 8887963
[TBL] [Abstract][Full Text] [Related]
17. Altered dopamine receptor mediated signal transmission in the striatum of aged rats.
May T; Sugawa M
Brain Res; 1993 Feb; 604(1-2):106-11. PubMed ID: 8457839
[TBL] [Abstract][Full Text] [Related]
18. Comparative effects of LSD and lisuride: clues to specific hallucinogenic drug actions.
White FJ
Pharmacol Biochem Behav; 1986 Feb; 24(2):365-79. PubMed ID: 3952127
[TBL] [Abstract][Full Text] [Related]
19. Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
Pugsley TA; Davis MD; Akunne HC; MacKenzie RG; Shih YH; Damsma G; Wikstrom H; Whetzel SZ; Georgic LM; Cooke LW
J Pharmacol Exp Ther; 1995 Dec; 275(3):1355-66. PubMed ID: 8531103
[TBL] [Abstract][Full Text] [Related]
20. Distribution of serotonin and dopamine receptors in Aplysia tissues: analysis by [3H]LSD binding and adenylate cyclase stimulation.
Drummond AH; Bucher F; Levitan IB
Brain Res; 1980 Feb; 184(1):163-77. PubMed ID: 7357415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
